Shots:

• The termination is based on P-III JAVELIN Ovarian PARP 100 study (B9991030) results assessing Bavencio (avelumab) + CT followed by avelumab + Talzenna (talazoparib) vs PBO in 9-000 patients with locally advanced or metastatic ovarian cancer
• The termination is due to its third failure with unmet degree of benefit observed with avelumab in ovarian cancer responding to its discontinuation & approval of AstraZeneca’s PARP Lynparza in ovarian cancer
• Bavencio (avelumab) is a mAb targeting PD-L1 protein while blocking PD-L1 interaction with PD-1 receptor. Talzenna (talazoparib) is a PARP inhibitor used in treatment of BRCA mutated breast cancer. In November 2014- Merck & Pfizer collaborated to co-develop & co-commercialize avelumab

Ref: Merck KGaA | Image: Merck KGaA